IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-30884-6.html
   My bibliography  Save this article

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Author

Listed:
  • Tal Patalon

    (Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services
    Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services)

  • Yaki Saciuk

    (Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services)

  • Asaf Peretz

    (Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services
    Internal Medicine COVID-19 Ward, Samson Assuta Ashdod University Hospital)

  • Galit Perez

    (Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services)

  • Yoav Lurie

    (Liver unit, Shaare Zedek City Center Campus)

  • Yasmin Maor

    (Tel Aviv University
    Edith Wolfson Medical Centre)

  • Sivan Gazit

    (Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services
    Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services)

Abstract

The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2 mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as global discussions around the necessity and effectiveness of a fourth dose are already underway. By conducting a retrospective study implementing a test-negative case-control design, analyzing 546,924 PCR tests performed throughout January 2022 by 389,265 persons who received at least two doses, we find that the effectiveness in each month-since-vaccination decreases significantly. Compared to those vaccinated five months prior to the outcome period, on August 2021, relative protection against infection waned from 53.4% a month after vaccination to 16.5% three months after vaccination. These results suggest that there is a significant waning of vaccine effectiveness against the Omicron variant of the third dose of the BNT162b2 vaccine within a few months after administration. Additional information could assist to comprehensively estimate the effectiveness of the three-dose-strategy.

Suggested Citation

  • Tal Patalon & Yaki Saciuk & Asaf Peretz & Galit Perez & Yoav Lurie & Yasmin Maor & Sivan Gazit, 2022. "Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine," Nature Communications, Nature, vol. 13(1), pages 1-7, December.
  • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30884-6
    DOI: 10.1038/s41467-022-30884-6
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-30884-6
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-022-30884-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Barak Mizrahi & Roni Lotan & Nir Kalkstein & Asaf Peretz & Galit Perez & Amir Ben-Tov & Gabriel Chodick & Sivan Gazit & Tal Patalon, 2021. "Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine," Nature Communications, Nature, vol. 12(1), pages 1-5, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Michal Canetti & Noam Barda & Mayan Gilboa & Victoria Indenbaum & Michal Mandelboim & Tal Gonen & Keren Asraf & Yael Weiss-Ottolenghi & Sharon Amit & Ram Doolman & Ella Mendelson & Dror Harats & Laure, 2022. "Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    2. Joseph A. Lewnard & Vennis Hong & Jeniffer S. Kim & Sally F. Shaw & Bruno Lewin & Harpreet Takhar & Marc Lipsitch & Sara Y. Tartof, 2023. "Increased vaccine sensitivity of an emerging SARS-CoV-2 variant," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
    3. Laura Pérez-Alós & Cecilie Bo Hansen & Jose Juan Almagro Armenteros & Johannes Roth Madsen & Line Dam Heftdal & Rasmus Bo Hasselbalch & Mia Marie Pries-Heje & Rafael Bayarri-Olmos & Ida Jarlhelt & Seb, 2023. "Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    4. Alejandro Jara & Cristobal Cuadrado & Eduardo A. Undurraga & Christian García & Manuel Nájera & María Paz Bertoglia & Verónica Vergara & Jorge Fernández & Heriberto García-Escorza & Rafael Araos, 2023. "Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile," Nature Communications, Nature, vol. 14(1), pages 1-7, December.
    5. Denis Mongin & Nils Bürgisser & Gustavo Laurie & Guillaume Schimmel & Diem-Lan Vu & Stephane Cullati & Delphine Sophie Courvoisier, 2023. "Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection," Nature Communications, Nature, vol. 14(1), pages 1-13, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ankita Leekha & Arash Saeedi & K M Samiur Rahman Sefat & Monish Kumar & Melisa Martinez-Paniagua & Adrian Damian & Rohan Kulkarni & Kate Reichel & Ali Rezvan & Shalaleh Masoumi & Xinli Liu & Laurence , 2024. "Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    2. Qinghong Fan & Jingrong Shi & Yanhong Yang & Guofang Tang & Mengling Jiang & Jiaojiao Li & Jingyan Tang & Lu Li & Xueliang Wen & Lieguang Zhang & Xizi Deng & Yaping Wang & Yun Lan & Liya Li & Ping Pen, 2022. "Clinical characteristics and immune profile alterations in vaccinated individuals with breakthrough Delta SARS-CoV-2 infections," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    3. Matan Levine-Tiefenbrun & Idan Yelin & Hillel Alapi & Esma Herzel & Jacob Kuint & Gabriel Chodick & Sivan Gazit & Tal Patalon & Roy Kishony, 2022. "Waning of SARS-CoV-2 booster viral-load reduction effectiveness," Nature Communications, Nature, vol. 13(1), pages 1-4, December.
    4. Christine D. Palmer & Ciaran D. Scallan & Lauren D. Kraemer Tardif & Melissa A. Kachura & Amy R. Rappaport & Daniel O. Koralek & Alison Uriel & Leonid Gitlin & Joshua Klein & Matthew J. Davis & Harshn, 2023. "GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    5. Raman, Shyam & Kriner, Douglas & Ziebarth, Nicolas & Simon, Kosali & Kreps, Sarah, 2022. "COVID-19 booster uptake among US adults: Assessing the impact of vaccine attributes, incentives, and context in a choice-based experiment," Social Science & Medicine, Elsevier, vol. 310(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30884-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.